Researchers found exemestane to be comparable to anastrozole in preventing recurrent breast cancer and overall survival. However, exemestane showed lower cholesterol levels and fewer reports of osteoporosis, while anastrozole had more side effects on blood tests and mood changes.
A meta-analysis reveals that postmenopausal women with breast cancer who use aromatase inhibitors are at a higher risk of developing cardiovascular disease. The study suggests that these women should be monitored for shorter durations of treatment to minimize this risk.
A retrospective study found that obese women with estrogen receptor-positive/HER2-negative breast cancer experienced significantly worse disease-free and overall survival rates compared to non-obese patients. Obesity was not associated with poorer outcomes in HER2-positive or triple-negative breast cancer subtypes.
A study of over 12 million women found that only half received annual mammograms, with rates varying by age group. The low rate has sparked theories on reasons behind non-compliance, including discomfort and lack of available screening centers.
Dr. George W. Sledge Jr is a pioneer in developing novel therapies for breast cancer. His work has improved the lives of countless cancer patients through anti-angiogenic therapy and molecular studies.
A study analyzing European Prospective Investigation into Cancer and Nutrition data found that current hormone therapy use increases the risk of ovarian cancer by 29%. The risk did not differ by type or duration of hormone therapy, suggesting a potential long-term hazard.
Researchers analyzed data from the Cancer Prevention Study II Nutrition Cohort and found that long-term statin use was not associated with overall cancer incidence or increased risk of common types of cancer. Instead, it was linked to lower risks of melanoma, endometrial cancer, and non-Hodgkin lymphoma.
A study found that physical activity reduces the risk of endometrial cancer, even among overweight women. Women exercising for 150 minutes per week had a 34% lower risk compared to inactive counterparts.
Despite strong evidence of its effectiveness, only one-third of eligible young women complete the recommended three-dose regimen for the human papillomavirus (HPV) vaccine. Persistent infection with certain HPV types may lead to cervical cancer.
Researchers found that women treated with aromatase inhibitors experience a wide range of side effects, including hot flashes, fatigue, and breast sensitivity. The study suggests that addressing these side effects is crucial for improving treatment adherence and patient outcomes.
A study by the American Association for Cancer Research found that 90% of children exposed to a smoker at home had detectable levels of tobacco carcinogens in their urine. The researchers also discovered a direct correlation between cigarettes smoked per day and tobacco metabolites in the children.
A study of over 46,500 prostate cancer patients found that long-term androgen deprivation therapy increases the risk of fractures, especially among older men with pre-existing conditions. The therapy was associated with a 20% increase in first fracture risk and a 57% increased risk of second fractures.
Researchers found distinct DNA alterations in lung tumors from smokers and never-smokers, suggesting two possible disease pathways. The study suggests that lung cancers in never-smokers require further investigation to improve detection and treatment strategies.
Researchers found that allopurinol reduced levels of Ki67 biomarker in normal tissue but not in adenoma tissue. The study suggests allopurinol may have some activity against colon carcinogenesis, providing a potential background for a large trial to reduce adenoma recurrence.
A study analyzing data from the Women's Health Initiative found that statin use did not lower the risk of colorectal cancer among postmenopausal women. Researchers identified no association between statin use and reduced risk for colorectal cancer, tumor location, stage, grade or histology.
A study published in Cancer Prevention Research found that gefitinib reduced pancreatic tumor incidence by 77% in mid-dose group and 100% in high-dose group. The compound also showed potential in preventing precursor lesions, with 67.6% of mice free of pancreatic intraepithelial neoplasms at 100 ppm dose.
A study found that high soy isoflavone intake was associated with a 30% decreased risk of invasive breast tumors and a 60% decreased risk of grade 1 tumors. In premenopausal women, the highest isoflavone intake reduced the risk of stage I disease, tumor size, and stage 2 breast cancer by significant margins.
A large prospective cohort study found that smoking significantly increased the risk of breast cancer progression and overall death among multiethnic women. Current or past smokers had a 39% higher rate of dying from breast cancer.
Duke University researchers identified a possible biomarker to measure breast cancer chemoprevention trial progress, allowing for smaller trials with fewer patients. This biomarker could indicate increased risk of breast cancer and be prevented by drugs targeting specific molecular signals.
Neonatal mice separated from their mothers for a prolonged period developed mammary tumors twice as fast as those with short or no maternal separation. Estrogen receptor alpha levels were also significantly higher in mice exposed to prolonged separation, increasing breast cancer risk.
A study found that Mexican-American women with breast cancer experienced an earlier onset of menopause, potentially reducing their risk due to shorter estrogen exposure. Weight gain during adulthood also reduced breast cancer risk, regardless of menopausal status.
Cancer Discovery is a new peer-reviewed journal from the American Association for Cancer Research (AACR), featuring game-changing research and review articles. The journal combines expertise from founding Editors-in-Chief Lewis C. Cantley and José Baselga, with executive editor Mark W. Landis.
Researchers found a microRNA binding variant linked to improved survival rates in early-stage colorectal cancer patients, particularly those with KRAS mutations. The variant, previously associated with poor outcomes, was unexpectedly beneficial due to an unidentified compensatory pathway controlling the gene.
Researchers found that FAK inhibitor Y15 effectively blocked colon cancer cell growth and viability in mice. The study showed promise for a new therapy by decreasing tumor growth and promoting apoptosis in mice treated with Y15.
University of Pittsburgh researchers have developed a 3D system to mimic colon cancer stem cell growth patterns. They found that some cancer stem cells produce differentiated cells, while others produce self-renewing cells, paving the way for testing new therapies.
Researchers identified two small-molecule inhibitors that effectively targeted FAK, an enzyme present in certain cancers. These inhibitors, Y11 and Y30, inhibited colon cancer-cell growth and decreased tumor formation, offering a potential for more effective and less toxic cancer therapies.
Researchers found a link between long telomeres and an increased risk of colorectal cancer in young-onset patients. The study suggests two distinct groups of colorectal cancer: one with accelerated aging due to telomere shortening, and another with longer telomeres.
A new investigational DNA methylation test has been shown to detect precancerous adenomas and cancers with high accuracy, detecting 64% of polyps over 1cm and 85% of cancers. The test is simple, non-invasive, and can be done from home, making it a promising alternative to traditional screening methods.
Groopman's research identified the link between environmental carcinogens and liver cancer, providing new prospects for prevention in high-risk populations worldwide. His work elucidated the role of aflatoxins in inducing hepatocellular carcinoma, a major cause of mortality in developing countries.
The AACR will honor two leading breast cancer researchers, Klaus Pantel and Alan Ashworth, for their groundbreaking work on detection and treatment of breast cancer. Pantel will receive the Outstanding Investigator Award for his pioneering research on minimal residual disease, while Ashworth will deliver the Distinguished Lectureship f...
A retrospective cohort study of 983 women found that non-Hispanic black and Hispanic women experienced significantly longer diagnostic delays than white women, regardless of insurance status. Diagnostic delay times ranged from 11.9 to 70.8 days, with uninsured black women facing the longest waits.
African-American women with breast cancer experience longer delays in treatment compared to white women, even when controlling for socioeconomic status and insurance type. The study found that the time to treatment lags behind recommended guidelines by an average of 12 days.
A recent study found that patients without private health insurance had significantly poorer cancer survival rates compared to those with insurance. The study, which analyzed data from 178,891 patients, also found that African-American patients were twice as likely to die within four years of diagnosis.
Data from a national survey reveals that nonwhite female cancer survivors receive significantly less social support than their white counterparts. The study suggests that this disparity may be linked to differences in engagement with moderate-intensity physical activity, which was found to be similar across racial groups.
A retrospective study found that African-American patients had a lower median overall survival rate due to factors such as age, stage, and type of treatment, rather than their race. Patients of other races, including Asian and Hispanic patients, had a better disease prognosis.
Researchers found that Puerto Rican women with triple-negative breast cancer had a higher risk of death from breast cancer, even after adjusting for age and cancer stage. Women under 50 years old with regional/distant disease were also more likely to die from their breast cancer.
Researchers discuss factors contributing to cancer disparities, including language barriers and lack of health literacy. Successful strategies include tailoring messages to specific audiences and promoting evidence-based programs like Body and Soul.
A group-based, holistic mind-body intervention was found to be equally effective in treating persistent fatigue and improving quality of life for breast cancer survivors across different racial groups. The program combined relaxation techniques, nutrition optimization, physical activity, and cognitive behavioral therapy.
Genetic tests are increasingly being offered directly to consumers in Puerto Rico, leading to higher awareness levels compared to previous U.S. population-based studies. However, the actual use of these tests is lower than expected, affecting specific groups such as smokers.
A study published by the American Association for Cancer Research found that vigorous exercise of more than two hours per week can significantly reduce the risk of developing breast cancer in postmenopausal African-American women. Women who engaged in such exercise had a 64% reduced risk compared to those who did not.
Researchers found a significant correlation between low socioeconomic status and late-stage, non-localized colorectal cancer diagnoses. Participants from less deprived neighborhoods had a lower incidence rate of 16.2%, while those from more disadvantaged areas had a higher incidence rate of 19.8%.
Researchers found that individuals with low DNA repair capacity have three times greater likelihood of developing non-melanoma skin cancer compared to those with high DRC. Low DRC levels were strongly associated with non-melanoma skin cancer, regardless of other risk factors.
A new study reveals that people with a history of cancer are 40% more likely to experience memory problems that interfere with daily functioning. The findings suggest that cancer itself is a key independent predictor of memory issues, going beyond previously recognized conditions like 'chemobrain'.
A study found that Mexican women who are exposed to environmental tobacco smoke are at a higher risk of developing breast cancer, with a threefold increased risk compared to those who do not smoke. The link between passive smoking and breast cancer remained regardless of menopausal status.
Vitamin D deficiency is associated with a higher likelihood of aggressive breast cancer in African-American women. Vitamin D levels were found to be 29.8 ng/ml in white women and 19.3 ng/ml in African-American women.
A new blood test called AccuPSA can detect rising prostate specific antigen levels after radical prostatectomy, allowing for earlier detection of cancer recurrence. This test has the potential to eliminate unnecessary treatments and improve health care costs by enabling earlier treatment with potentially better outcomes.
Researchers developed a novel, dual-platform technology to capture circulating tumor cells (CTCs) in breast cancer more efficiently than traditional methods. The On-Q-ity C5 chip captured 65% of human breast cancer cells compared to 45% with size-based and 16% with antibody affinity methods.
A new microRNA panel test has been developed to further subclassify non-small cell lung cancer, allowing for more accurate diagnosis and treatment decisions. This test has shown high sensitivity and specificity in distinguishing between subtypes of lung cancer.
A new microRNA screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity from a single plasma sample. The test has the potential to be safe, cheap, robust, accurate, and convenient for national screening programs.
Researchers found that circulating tumor cells (CTCs) can provide real-time information on patient's current disease state through biomarker assessments. The technology has potential for non-invasive detection and analysis of cancer biomarkers.